Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 18/20 | 0.51 |
| ▸ | S1PR5 | Q9H228 | 10/20 | 0.49 |
| ▸ | S1PR4 | O95977 | 8/20 | 0.49 |
| ▸ | S1PR3 | Q99500 | 8/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3456620 | 1.00 | S1PR1 (0.51) | S1PR1S1PR5S1PR4S1PR3TP53 | |
| SCHEMBL3456348 | 0.94 | S1PR1 (0.46) | S1PR1S1PR5S1PR4S1PR3TP53 | |
| SCHEMBL3456347 | 0.94 | S1PR1 (0.46) | S1PR1S1PR5S1PR4S1PR3TP53 | |
| SCHEMBL3456527 | 0.92 | S1PR1 (0.51) | S1PR1S1PR5S1PR4S1PR3TP53 | |
| SCHEMBL3456549 | 0.92 | S1PR1 (0.51) | S1PR1S1PR5S1PR4S1PR3TP53 | |
| SCHEMBL3455821 | 0.90 | S1PR1 (0.58) | S1PR1S1PR5S1PR4S1PR3TP53 | |
| SCHEMBL3455823 | 0.90 | S1PR1 (0.58) | S1PR1S1PR5S1PR4S1PR3TP53 | |
| SCHEMBL3456341 | 0.87 | S1PR1 (0.57) | S1PR1S1PR5S1PR4S1PR3 | |
| SCHEMBL3456339 | 0.87 | S1PR1 (0.57) | S1PR1S1PR5S1PR4S1PR3 | |
| SCHEMBL3457160 | 0.87 | S1PR1 (0.64) | S1PR1S1PR5S1PR4S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070270438-A1 | CYCLOALKYLAMINO ACID DERIVATIVES | PFIZER INC | 2007-11-22 | — | — | US | claimed |
| EP-2258700-A1 | Cycloalkylamino acid derivatives and pharmaceutical compositions thereof | Pfizer Products Inc. (US) | 2010-12-08 | — | — | EP | disclosed |
| US-20100120794-A1 | Cycloalkylamino Acid Derivatives | BHATTACHARYA SAMIT KUMAR | 2010-05-13 | — | — | US | disclosed |
| US-7671043-B2 | Cycloalkylamino acid derivatives | PFIZER INC (US) | 2010-03-02 | — | — | US | disclosed |
| US-20070270438-A1 | CYCLOALKYLAMINO ACID DERIVATIVES | PFIZER INC | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120794-A1 | Cycloalkylamino Acid Derivatives | CCND1, CCND2, CCND3 | S1PR1 104/4885S1PR5 248/4885S1PR4 254/4885 |
| US-20070270438-A1 | CYCLOALKYLAMINO ACID DERIVATIVES | CCND1, CCND2, CCND3 | S1PR1 104/4885S1PR5 248/4885S1PR4 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.